Investing In Digital: Slow And Steady May Win This Race
Getting out the gates early is usually the playbook for VC, however when it comes to new technologies with untested commercial pipelines, waiting and seeing may be a smarter approach.
You may also be interested in...
Novo Nordisk’s new generation of GLP-1 products have led to never-before-seen rates of medication-induced weight loss but require a lifelong commitment from patients to maintain these results – a commitment the market may not be able to rely on, since patients have not generally tended to stay on GLP-1 medications long-term.
Sofinnova Partners has played a key role in defining the medtech investment space for the past 50 years, helping bring to market a plethora of life-saving technologies, even when they appear, initially, to be risky.
Medtronic is dropping plans to acquire EOFlow, which has faced numerous patent lawsuits from Insulet.